A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.

J Clin Med · 2020 · PMC7767204 · PMID 33371271

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

[ 41 ] stated that there is a clear trend that HCC patients with HBV infection have survival benefit in lenvatinib treatment over sorafenib treatment.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.